Sunil Badve
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
683
Citations
42,773
Est. group size
—
Recurring co-author estimate
Active years
37
Publishing since 1990
Sunil Badve studies the diagnosis and treatment of cancer, with a strong focus on breast cancer, using pathology (the microscopic examination of tissue) combined with molecular testing and artificial intelligence. Much of the recent work develops computational tools that analyze tissue images and genomic data to predict how patients will respond to therapy and to estimate their prognosis. The work also covers thymic epithelial tumors and the role of the immune system in cancer treatment.
Publication activity has been steady at roughly 20-35 papers per year over the past decade, with one exceptionally high-output year in 2023.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors
JCO Precision Oncology · 2026
- MuTriM: A multiscale deep learning model integrating longitudinal radiomics and pathomic features for predicting recurrence and adjuvant radiation benefit in breast cancer
European Journal of Cancer · 2026
- Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy
Cancer Immunology Immunotherapy · 2026
- 114 Impact of Lehmann’s Classification on Pathological Complete Response after Neoadjuvant Therapy in Triple-Negative Breast Cancer - Systematic Review and Single-Arm Meta-analysis
Laboratory Investigation · 2026
- WCN26-5467 ASPIrin to Reduce Events in Dialysis (ASPIRED) trial: a pragmatic, registry-based, double-blind randomized clinical trial
Kidney International Reports · 2026
- Correction: Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy
Cancer Immunology Immunotherapy · 2026
- Virtual AI-informed immunocyte profiling (VAIP) from H&E as a predictor of multi-cancer prognosis.
Journal of Clinical Oncology · 2026
- Prognostic validation of artificial intelligence (AI)–based Stratipath breast risk stratification in TAILORx.
Journal of Clinical Oncology · 2026
- The lineage-defining transcription factors FOXA1 and POU2F3 as markers of poor prognosis across two large cohorts of thymic malignancies.
Journal of Clinical Oncology · 2026
- Data from Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation
2026
- Supplementary Data1 from Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation
2026
- EA1181: Accuracy of pre-surgery MRI to predict pathologic complete response after taxane, trastuzumab, and pertuzumab (THP) in HER2-positive breast cancer.
Journal of Clinical Oncology · 2026
- Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ
JAMA Oncology · 2025
- Artificial intelligence in digital pathology — time for a reality check
Nature Reviews Clinical Oncology · 2025
- Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management
Modern Pathology · 2025
- Journal of Clinical Oncology×35
- Cancer Research×32
- npj Breast Cancer×10
- Modern Pathology×9
- Publisher×7
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile